E2F-1 cooperates with topoisomerase II inhibition and DNA damage to selectively augment p53-independent apoptosis

Molecular and Cellular Biology

Volumn 17, Issue 3, 1997, Pages 1049-1056

  Nip, John ^a   Strom, David K ^a   Fee, Brian E ^a   Zambetti, Gerard ^a   Cleveland, John L ^a,b   Hiebert, Scott W ^a,c  

^a ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^b UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

^c VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DNA TOPOISOMERASE (ATP HYDROLYSING); DOXORUBICIN; ETOPOSIDE; FLUOROURACIL; INTERLEUKIN 3; PROTEIN P53; TRANSCRIPTION FACTOR E2F;

APOPTOSIS; ARTICLE; BONE MARROW CELL; CANCER THERAPY; CARCINOGENESIS; CELL CYCLE; CELL CYCLE S PHASE; CELL DEATH; CELL VIABILITY; CYTOTOXICITY; DNA DAMAGE; ENZYME INHIBITION; HUMAN; HUMAN CELL; IMMUNOBLOTTING; MUTATION; PRIORITY JOURNAL;

EID: 0031024991     PISSN: 02707306     EISSN: None     Source Type: Journal    
DOI: 10.1128/MCB.17.3.1049     Document Type: Article

References (56)

1. Adams, P. D., and W. G. Kaelin, Jr. 1995. Transcriptional control by E2F. Semin. Cancer Biol. 6:99-108.
2. Bates, S., and G. Peters. 1995. Cyclin D1 as a cellular proto-oncogene. Semin. Cancer Biol. 6:73-82.
3. Cao, L., B. Faha, M. Dembski, L. H. Tsai, E. Harlow, and N. Dyson. 1992. Independent binding of the retinoblastoma protein and p107 to the transcription factor E2F. Nature 355:176-179.
4. Chellappan, S. P., S. Hiebert, M. Mudryj, J. M. Horowitz, and J. R. Nevins. 1991. The E2F transcription factor is a cellular target for the RB protein. Cell 65:1053-1061.
5. Cleveland, J. L., B. F. Fee, C. Rodriguez-Galindo, J. Nip, G. Zambetti, S. W. Hiebert, and G. Packham. Bcl-2 is a selective target for feedback repression by oncogenes which induce apoptosis. Submitted for publication.
6. Cobrinik, D., P. Whyte, D. S. Peeper, T. Jacks, and R. A. Weinberg. 1993. Cell cycle-specific association of E2F with the p130 E1A-binding protein. Genes Dev. 7:2392-2404.
7. DeGregori, J., T. Kowalik, and J. R. Nevins. 1995. Cellular targets for activation by the E2F1 transcription factor include DNA synthesis- and G1/S-regulatory genes. Mol. Cell. Biol. 15:4215-4224.
8. DeGregori, J., G. Leone, K. Ohtani, A. Miron, and J. R. Nevins. 1995. E2F-1 accumulation bypasses a G1 arrest resulting from the inhibition of G1 cyclin-dependent kinase activity. Genes Dev. 9:2873-2887.
9. Dobrowolski, S. F., D. W. Stacey, M. L. Harter, J. T. Stine, and S. W. Hiebert. 1994. An E2F dominant negative mutant blocks E1A induced cell cycle progression. Oncogene 9:2605-2612.
10. Donaldson, K. L., G. L. Goolsby, and A. F. Wahl. 1994. Cytotoxicity of the anticancer agents cisplatin and taxol during cell proliferation and the cell cycle. Int. J. Cancer 57:847-855.
11. Dyson, N. 1994. pRB, p107 and the regulation of the E2F transcription factor. J. Cell Sci. 18(Suppl.):81-87.
12. Gillett, C., V. Fantl, R. Smith, C. Fisher, J. Bartek, C. Dickson, D. Barnes, and G. Peters. 1994. Amplification and overexpression of cyclin D1 in breast cancer detected by immunohistochemical staining. Cancer Res. 54:1812-1817.
13. Hainsworth, J. D., and F. A. Greco. 1995. Etoposide: twenty years later. Ann. Oncol. 6:323-341.
14. Hamel, P. A., R. M. Gill, R. A. Phillips, and B. L. Gallie. 1992. Transcriptional repression of the E2-containing promoters EIIaE, c-myc, and RB1 by the product of the RB1 gene. Mol. Cell. Biol. 12:3431-3438.
15. Hannon, G. J., and D. Beach. 1994. p15INK4B is a potential effector of TGF-B-induced cell cycle arrest. Nature 371:257-261.
16. Hengstschläger, M., E. Hengstschläger-Ottnad, O. Pusch, and E. Wawra. 1996. The role of p16 in the E2F-dependent thymidine kinase regulation. Oncogene 12:1635-1643.
17. Hiebert, S. W., S. P. Chellappan, J. M. Horowitz, and J. R. Nevins. 1992. The interaction of RB with E2F coincides with an inhibition of the transcriptional activity of E2F. Genes Dev. 6:177-185.
18. Hiebert, S. W., G. Packham, D. K. Strom, R. Haffner, M. Oren, G. Zambetti, and J. L. Cleveland. 1995. E2F-1:DP-1 induces p53 and overrides survival factors to trigger apoptosis. Mol. Cell. Biol. 15:6864-6874.
19. Hinds, P., C. Finlay, and A. J. Levine. 1989. Mutation is required to activate the p53 gene for cooperation with the ras oncogene and transformation. J. Virol. 63:739-746.
20. Ishida, R., M. Sato, T. Narita, K. R. Utsumi, T. Nishimoto, T. Morita, H. Nagata, and T. Andoh. 1994. Inhibition of DNA topoisomerase II by ICRF-193 induces polyploidization by uncoupling chromosome dynamics from other cell cycle events. J. Cell Biol. 126:1341-1351.
21. Johnson, D. G., W. D. Cress, L. Jakoi, and J. R. Nevins. 1994. Oncogenic capacity of the E2F1 gene. Proc. Natl. Acad. Sci. USA 91:12823-12827.
22. Johnson, D. G., J. K. Schwarz, W. D. Cress, and J. R. Nevins. 1993. Expression of transcription factor E2F1 induces quiescent cells to enter S phase. Nature 365:349-352.
23. Kato, J., H. Matsushime, S. W. Hiebert, M. E. Ewen, and C. J. Sherr. 1993. Direct binding of cyclin D to the retinoblastoma gene product (pRb) and pRb phosphorylation by the cyclin D-dependent kinase CDK4. Genes Dev. 7:331-342
24. Kobayashi, H., K. Kitano, H. Saito, K. Aoki, A. Narita, N. Terada, M. Sonoyama, K. Uchimaru, T. Machii, and T. Motokura. 1995. Overexpression of the PRAD1 oncogene in a patient with prolymphocytic leukemia with t(11;14)(q13;q32). Cancer Genet. Cytogenet. 84:69-72.
25. Kowalik, T. F., J. DeGregori, J. K. Schwarz, and J. R. Nevins. 1995. E2F1 overexpression in quiescent fibroblasts leads to induction of cellular DNA synthesis and apoptosis. J. Virol. 69:2491-2500.
26. Krek, W., M. E. Ewen, S. Shirodkar, Z. Arany, W. G. Kaelin, Jr., and D. M. Livingston. 1994. Negative regulation of the growth-promoting transcription factor E2F-1 by a stably bound cyclin A-dependent protein kinase. Cell 78:161-172.
27. Krek, W., G. Xu, and D. M. Livingston. 1995. Cyclin A-kinase regulation of E2F-1 DNA binding function underlies suppression of an S phase checkpoint. Cell 83:1149-1158.
28. Krishan, A. 1975. Rapid flow cytometric analysis of mammalian cell cycle by propidium iodide staining. J. Cell Biol. 66:188-193.
29. La Thangue, N. B. 1994. DP and E2F proteins: components of a heterodimeric transcription factor implicated in cell cycle control. Curr. Opin. Cell Biol. 6:443-450.
30. Logan, T. J., D. L. Evans, W. E. Mercer, M.-A. Bjornsti, and D. J. Hall. 1995. Expression of a deletion mutant of the E2F1 transcription factor in fibroblasts lengthens S phase and increases sensitivity to S phase-specific toxins. Cancer Res. 55:2883-2891.
31. Logan, T. J., K. L. Jordan, and D. J. Hall. 1994. Altered shape and cell cycle characteristics of fibroblasts expressing the E2F1 transcription factor. Mol. Biol. Cell 5:667-678.
32. Lowe, S. W., H. E. Ruley, T. Jacks, and D. E. Housman. 1993. p53-dependent apoptosis modulates the cytotoxicity of anticancer agents. Cell 74:957-967.
33. Melillo, R. M., K. Helin, D. R. Lowy, and J. T. Schiller. 1994. Positive and negative regulation of cell proliferation by E2F-1: influence of protein level and human papillomavirus oncoproteins. Mol. Cell. Biol. 14:8241-8249.
34. Mudryj, M., S. H. Devoto, S. W. Hiebert, T. Hunter, J. Pines, and J. R. Nevins. 1991. Cell cycle regulation of the E2F transcription factor involves an interaction with cyclin A. Cell 65:1243-1253.
35. Nevins, J. R. 1992. E2F: a link between the Rb tumor suppressor protein and viral oncoproteins. Science 258:424-429.
36. Oltvai, Z. N., C. L. Milliman, and S. J. Korsmeyer. 1993. Bcl-2 heterodimerizes in vivo with a conserved homolog, Bax, that accelerates programmed cell death. Cell 74:609-619.
37. Pagano, M., G. Draetta, and P. Jansen-Durr. 1992. Association of cdk2 kinase with the transcription factor E2F during S phase. Science 255:1144-1147.
38. Prokocimer, M., and V. Rotter. 1994. Structure and function of p53 in normal cells and their aberrations in cancer cells: projection on the hematologic cell lineages. Blood 84:2391-2411.
39. Qin, X. Q., D. M. Livingston, W. G. Kaelin, Jr., and P. D. Adams. 1994. Deregulated transcription factor E2F-1 expression leads to S-phase entry and p53-mediated apoptosis. Proc. Natl. Acad. Sci. USA 91:10918-10922.
40. Roca, J., R. Ishida, J. M. Berger, T. Andoh, and J. C. Wang. 1994. Antitumor bisdioxopiperazines inhibit yeast DNA topoisomerase II by trapping the enzyme in the form of a closed protein clamp. Proc. Natl. Acad. Sci. USA 91:1781-1785.
41. Roca, J., and J. C. Wang. 1992. The capture of a DNA double helix by an ATP-dependent protein clamp: a key step in DNA transport by type II DNA topoisomerases. Cell 71:833-840.
42. Scheffner, M., K. Munger, J. C. Byrne, and P. M. Howley. 1991. The state of the p53 and retinoblastoma genes in human cervical carcinoma cell lines. Proc. Natl. Acad. Sci. USA 88:5523-5327.
43. Serrano, M., G. J. Hannon, and D. Beach. 1993. A new regulatory motif in cell-cycle control causing specific inhibition of cyclinD/cdk4. Nature 366: 704-707.
44. Shan, B., and W. H. Lee. 1994. Deregulated expression of E2F-1 induces S-phase entry and leads to apoptosis. Mol. Cell. Biol. 14:8166-8173.
45. Shirodkar, S., M. Ewen, J. A. DeCaprio, J. Morgan, D. M. Livingston, and T. Chittenden. 1992. The transcription factor E2F interacts with the retinoblastoma product and a p107-cyclin A complex in a cell cycle-regulated manner. Cell 68:157-166.
46. Singh, P., S. H. Wong, and W. Hong. 1994. Overexpression of E2F-1 in rat embryo fibroblasts leads to neoplastic transformation. EMBO J. 13:3329-3338.
47. Smith, P. J., and S. Souès. 1994. Multilevel therapeutic targeting by topoisomerase inhibitors. Br. J. Cancer Suppl. 23:47-51.
48. Strasser, A., A. W. Harris, T. Jacks, and S. Cory. 1994. DNA damage can induce apoptosis in proliferating lymphoid cells via p53-independent mechanisms inhibitable by Bcl-2. Cell 79:329-339.
49. Vaux, D. L., S. Cory, and J. M. Adams. 1988. Bcl-2 gene promotes haemopoietic cell survival and cooperates with c-myc to immortalize pre-B cells. Nature 335:440-442.
50. Weinberg, R. A. 1991. Tumor suppressor genes. Science 254:1138-1146.
51. Weintraub, S. J., C. A. Prater, and D. C. Dean. 1992. Retinoblastoma protein switches the E2F site from positive to negative element. Nature 358:259-261.
52. Williams, B. O., L. Remington, D. M. Albert, S. Mukai, R. T. Bronson, and T. Jacks. 1994. Cooperative tumorigenic effects of germline mutations in Rb and p53 Nat. Genet. 7:480-484.
53. Wu, X., and A. J. Levine. 1994. p53 and E2F-1 cooperate to mediate apoptosis Proc. Natl. Acad. Sci. USA 91:3602-3606.
54. Xu, G., D. M. Livingston, and W. Krek. 1995. Multiple members of the E2F transcription factor family are the products of oncogenes. Proc. Natl. Acad. Sci. USA 92:1357-1361.
55. Xu, M., K. A. Sheppard, C. Y. Peng, A. S. Yee, and H. Piwnica-Worms. 1994. Cyclin A/CDK2 binds directly to E2F-1 and inhibits the DNA-binding activity of E2F-1/DP-1 by phosphorylation. Mol. Cell. Biol. 14:8420-8431.
56. Zhang, Y., and S. P. Chellappan. 1995. Cloning and characterization of human DP2, a novel dimerization partner of E2F. Oncogene 10:2085-2093.